StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Research analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a report released on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of NASDAQ PULM opened at $5.78 on Thursday. The firm has a market capitalization of $21.10 million, a PE ratio of -2.19 and a beta of 1.54. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $8.44. The business’s fifty day moving average price is $3.89 and its two-hundred day moving average price is $2.69.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.